CORT113176

DRUG2 trials

Sponsors

Corcept Therapeutics Inc., Corcept Therapeutics

Conditions

Amyotrophic Lateral SclerosisHealthy Adults

Phase 1

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

CompletedNCT04994743

Corcept TherapeuticsHealthy Adults

Start: 2021-07-13End: 2021-09-30Updated: 2021-10-11

Phase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis (DAZALS)

Active, not recruitingCTIS2024-514082-19-00

Corcept Therapeutics Inc.Amyotrophic Lateral Sclerosis

Start: 2022-11-04Target: 225Updated: 2025-09-30